© 1996 by Oxford University Press
Journal of the National Cancer Institute, Vol. 88, No. 21, 1543-1549,
November 6, 1996
© 1996 Oxford University Press
Randomized Trial of Two Versus Five Years of Adjuvant Tamoxifen for Postmenopausal Early Stage Breast Cancer
Swedish Breast Cancer Cooperative Group*
Lars E. Rutqvist, M.D., Oncologic Centre, Karolinska Hospital, S-104 01 Stockholm, Sweden.
Background: Postsurgical treatment with tamoxifen has been shown to improve overall survival among patients with early stage breast cancer. However, the optimal duration of tamoxifen treatment remains controversial. Purpose: A multicenter, randomized trial was initiated in Sweden in the early 1980s to compare 2 years with 5-years of adjuvant tamoxifen in the treatment of postmenopausal women younger than 75 years of age who had early stage, axillary lymph node-negative or -positive, invasive disease. Methods: The trial was planned and organized by the Swedish Breast Cancer Group, and it involved five regional breast cancer study organizations (South Sweden, South-East Sweden, Stockholm, Uppsala-Örebro, and North Sweden). During the period from 1983 through 1991, a total of 3887 patients were entered in the trial; 3545 (91%) women remained alive and recurrence free at 2 years and could thus contribute meaningful information to the 2-year (n = 1801) versus 5 year (n = 1744) comparison. Primary surgery consisted of either modified radical mastectomy or breast-conserving surgery. Radiation therapy was indicated for patients with lymph node-positive disease and was generally offered to all women who were treated with breast-conserving surgery. Only 89 (2.5%) of the 3545 women who were recurrence free at 2 years received adjuvant chemotherapy concurrently with tamoxifen. Twenty-milligram daily doses of tamoxifen were used at two centers, and 40-mg daily doses were used at the remaining three centers. Estrogen receptor status of the tumor was known for 2987 women (77% of the entered patients). Primary end points in the trial were event-free survival (local-regional recurrence, distant metastasis, contralateral breast cancer, or death) and overall survival. Survival curves were estimated by use of the life-table method. The Cox proportional hazards model was used to make comparisons between the 2- and 5-year treatment groups. Results: Patients assigned to receive 5 years of tamoxifen, compared with 2 years of tamoxifen, experienced statistically significant improvements in event-free survival (relative hazard = 0.82; 95% confidence interval [CI] = 0.71–0.96) and overall survival (relative hazard = 0.82; 95% CI = 0.69–0.99). These findings translate into an 18% relative reduction in both first events (95% CI = 4%–29%) and mortality (95% CI = 1%–31%) with the longer treatment. Overall survival at 10 years was estimated to be 80% among patients in the 5-year tamoxifen group who were alive and recurrence free at 2 years, compared with 74% among corresponding patients in the 2-year treatment group. The benefit associated with the longer treatment extended to women with lymph node-positive as well as lymph node-negative disease, but it appeared to be restricted to women whose tumors were classified as estrogen receptor positive.Conclusion: Five years of adjuvant tamoxifen is more beneficial than 2 years in the treatment of postmenopausal women with estrogen receptor-positive, early stage, invasive breast cancer. [J Natl Cancer Inst 1996;88:1543–9]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. P. Mamounas Facilitating Breast-Conserving Surgery and Preventing Recurrence: Aromatase Inhibitors in the Neoadjuvant and Adjuvant Settings Ann. Surg. Oncol., March 1, 2008; 15(3): 691 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Partridge, A. LaFountain, E. Mayer, B. S. Taylor, E. Winer, and A. Asnis-Alibozek Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast Cancer J. Clin. Oncol., February 1, 2008; 26(4): 556 - 562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Kahn Moving Research From Bench to Bedside to Community: There Is Still More to Do J. Clin. Oncol., February 1, 2008; 26(4): 523 - 526. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Bertelsen, L. Bernstein, J. H. Olsen, L. Mellemkjaer, R. W. Haile, C. F. Lynch, K. E. Malone, H. Anton-Culver, J. Christensen, B. Langholz, et al. Effect of Systemic Adjuvant Treatment on Risk for Contralateral Breast Cancer in the Women's Environment, Cancer and Radiation Epidemiology Study J Natl Cancer Inst, January 2, 2008; 100(1): 32 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Gruvberger-Saal, P.-O. Bendahl, L. H. Saal, M. Laakso, C. Hegardt, P. Eden, C. Peterson, P. Malmstrom, J. Isola, A. Borg, et al. Estrogen Receptor {beta} Expression Is Associated with Tamoxifen Response in ER{alpha}-Negative Breast Carcinoma Clin. Cancer Res., April 1, 2007; 13(7): 1987 - 1994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. V. Ivshina, J. George, O. Senko, B. Mow, T. C. Putti, J. Smeds, T. Lindahl, Y. Pawitan, P. Hall, H. Nordgren, et al. Genetic Reclassification of Histologic Grade Delineates New Clinical Subtypes of Breast Cancer Cancer Res., November 1, 2006; 66(21): 10292 - 10301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Partridge Non-adherence to endocrine therapy for breast cancer Ann. Onc., February 1, 2006; 17(2): 183 - 184. [Full Text] [PDF]
|
|
|
|
|
|
B. Nordenskjold, J. Rosell, L.-E. Rutqvist, P.-O. Malmstrom, J. Bergh, N.-O. Bengtsson, T. Hatschek, A. Wallgren, and J. Carstensen Coronary Heart Disease Mortality After 5 Years of Adjuvant Tamoxifen Therapy: Results from a Randomized Trial J Natl Cancer Inst, November 2, 2005; 97(21): 1609 - 1610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Jirstrom, L Ryden, L Anagnostaki, B Nordenskjold, O Stal, S Thorstenson, G Chebil, P-E Jonsson, M Ferno, and G Landberg Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial J. Clin. Pathol., November 1, 2005; 58(11): 1135 - 1142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Jirstrom, M. Stendahl, L. Ryden, A. Kronblad, P.-O. Bendahl, O. Stal, G. Landberg, and The South Swedish and Southeast Swedish Breast Can Adverse Effect of Adjuvant Tamoxifen in Premenopausal Breast Cancer with Cyclin D1 Gene Amplification Cancer Res., September 1, 2005; 65(17): 8009 - 8016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E.R. Harris, V. J. Christensen, W.-T. Hwang, K. Fox, and L. J. Solin Impact of Concurrent Versus Sequential Tamoxifen With Radiation Therapy in Early-Stage Breast Cancer Patients Undergoing Breast Conservation Treatment J. Clin. Oncol., January 1, 2005; 23(1): 11 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Buzdar and C. Macahilig How Rapidly Do Oncologists Respond to Clinical Trial Data? Oncologist, January 1, 2005; 10(1): 15 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sverrisdottir, T. Fornander, H. Jacobsson, E. von Schoultz, and L.E. Rutqvist Bone Mineral Density Among Premenopausal Women With Early Breast Cancer in a Randomized Trial of Adjuvant Endocrine Therapy J. Clin. Oncol., September 15, 2004; 22(18): 3694 - 3699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L Jones and A. U Buzdar A review of adjuvant hormonal therapy in breast cancer Endocr. Relat. Cancer, September 1, 2004; 11(3): 391 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Coombes, E. Hall, L. J. Gibson, R. Paridaens, J. Jassem, T. Delozier, S. E. Jones, I. Alvarez, G. Bertelli, O. Ortmann, et al. A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer N. Engl. J. Med., March 11, 2004; 350(11): 1081 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sacco, M. Valentini, M. Belfiglio, F. Pellegrini, G. De Berardis, M. Franciosi, and A. Nicolucci Randomized Trial of 2 Versus 5 Years of Adjuvant Tamoxifen for Women Aged 50 Years or Older With Early Breast Cancer: Italian Interdisciplinary Group for Cancer Evaluation Study of Adjuvant Treatment in Breast Cancer 01 J. Clin. Oncol., June 15, 2003; 21(12): 2276 - 2281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Schmid, R. Jakesz, H. Samonigg, E. Kubista, M. Gnant, C. Menzel, M. Seifert, K. Haider, S. Taucher, B. Mlineritsch, et al. Randomized Trial of Tamoxifen Versus Tamoxifen Plus Aminoglutethimide as Adjuvant Treatment in Postmenopausal Breast Cancer Patients With Hormone Receptor-Positive Disease: Austrian Breast and Colorectal Cancer Study Group Trial 6 J. Clin. Oncol., March 15, 2003; 21(6): 984 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Partridge, P. S. Wang, E. P. Winer, and J. Avorn Nonadherence to Adjuvant Tamoxifen Therapy in Women With Primary Breast Cancer J. Clin. Oncol., February 15, 2003; 21(4): 602 - 606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Curigliano, M. Colleoni, G. Renne, G. Mazzarol, R. Gennari, G. Peruzzotti, F. de Braud, C. Robertson, E. Maiorano, P. Veronesi, et al. Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay Ann. Onc., June 1, 2002; 13(6): 895 - 902. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Partridge, J. Avorn, P. S. Wang, and E. P. Winer Adherence to Therapy With Oral Antineoplastic Agents J Natl Cancer Inst, May 1, 2002; 94(9): 652 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gunnarsson, B. M. Olsson, and O. Stal Abnormal Expression of 17{beta}-Hydroxysteroid Dehydrogenases in Breast Cancer Predicts Late Recurrence Cancer Res., December 1, 2001; 61(23): 8448 - 8451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 National Institutes of Health Consensus Developmen National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000 J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 5 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Bryant, B. Fisher, and J. Dignam Duration of Adjuvant Tamoxifen Therapy J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 56 - 61. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Gruvberger, M. Ringner, Y. Chen, S. Panavally, L. H. Saal, A. Borg, M. Ferno, C. Peterson, and P. S. Meltzer Estrogen Receptor Status in Breast Cancer Is Associated with Remarkably Distinct Gene Expression Patterns Cancer Res., August 1, 2001; 61(16): 5979 - 5984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Knoop, S. M. Bentzen, M. M. Nielsen, B. B. Rasmussen, and C. Rose Value of Epidermal Growth Factor Receptor, HER2, p53, and Steroid Receptors in Predicting the Efficacy of Tamoxifen in High-Risk Postmenopausal Breast Cancer Patients J. Clin. Oncol., July 15, 2001; 19(14): 3376 - 3384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000 J Natl Cancer Inst, July 4, 2001; 93(13): 979 - 989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Fisher, J. Dignam, J. Bryant, and N. Wolmark Five Versus More Than Five Years of Tamoxifen for Lymph Node-Negative Breast Cancer: Updated Findings From the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized Trial J Natl Cancer Inst, May 2, 2001; 93(9): 684 - 690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Stewart, R. J. Prescott, and A. P. M. Forrest Scottish Adjuvant Tamoxifen Trial: a Randomized Study Updated to 15 Years J Natl Cancer Inst, March 21, 2001; 93(6): 456 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K. Linderholm, T. Lindahl, L. Holmberg, S. Klaar, J. Lennerstrand, R. Henriksson, and J. Bergh The Expression of Vascular Endothelial Growth Factor Correlates with Mutant p53 and Poor Prognosis in Human Breast Cancer Cancer Res., March 1, 2001; 61(5): 2256 - 2260. [Abstract] [Full Text]
|
|
|
|
|
|
K. Holli, R. Valavaara, G. Blanco, V. Kataja, P. Hietanen, M. Flander, E. Pukkala, and H. Joensuu Safety and Efficacy Results of a Randomized Trial Comparing Adjuvant Toremifene and Tamoxifen in Postmenopausal Patients With Node-Positive Breast Cancer J. Clin. Oncol., October 20, 2000; 18(20): 3487 - 3494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Delozier, M. Spielmann, J. Mace-Lesec'h, M. Janvier, C. Hill, B. Asselain, J.-P. Julien, B. Weber, L. Mauriac, J.-C. Petit, et al. Tamoxifen Adjuvant Treatment Duration in Early Breast Cancer: Initial Results of a Randomized Study Comparing Short-Term Treatment With Long-Term Treatment J. Clin. Oncol., October 20, 2000; 18(20): 3507 - 3512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Hrung, C. P. Langlotz, S. G. Orel, K. R. Fox, M. D. Schnall, and J. S. Schwartz Cost-effectiveness of MR Imaging and Core-Needle Biopsy in the Preoperative Work-up of Suspicious Breast Lesions Radiology, October 1, 1999; 213(1): 39 - 49. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Baum and J. Houghton Contribution of randomised controlled trials to understanding and management of early breast cancer BMJ, August 28, 1999; 319(7209): 568 - 571. [Full Text]
|
|
|
|
|
|
A.-C. Lundin, P. Soderkvist, B. Eriksson, M. Bergman-Jungestrom, and S. Wingren Association of Breast Cancer Progression with a Vitamin D Receptor Gene Polymorphism Cancer Res., May 1, 1999; 59(10): 2332 - 2334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. K. Osborne Tamoxifen in the Treatment of Breast Cancer N. Engl. J. Med., November 26, 1998; 339(22): 1609 - 1618. [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Macgregor and V. C. Jordan Basic Guide to the Mechanisms of Antiestrogen Action Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Rea, C. Poole, and R. Gray Adjuvant tamoxifen: how long before we know how long? BMJ, May 16, 1998; 316(7143): 1518 - 1519. [Full Text]
|
|
|
|
 |
|
 Y. Hozumi, M. Kawano, T. Saito, and M. Miyata Effect of Tamoxifen on Serum Lipid Metabolism J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1633 - 1635. [Abstract] [Full Text]
|
|
|
|
|
|
K. Yao and V. C. Jordan Questions about Tamoxifen and the Future Use of Antiestrogens Oncologist, April 1, 1998; 3(2): 104 - 110. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. Sourla, S. Luo, C. Labrie, A. Belanger, and F. Labrie Morphological Changes Induced by 6-Month Treatment of Intact and Ovariectomized Mice with Tamoxifen and the Pure Antiestrogen EM-800 Endocrinology, December 1, 1997; 138(12): 5605 - 5617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Hudis and L. Norton Adjuvant Drug Treatment for Resectable Breast Cancer Oncologist, December 1, 1997; 2(6): 351 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Tamoxifen for Early Breast Cancer: How Long Is Optimal? Journal Watch Women's Health, January 1, 1997; 1997(101): 6 - 6. [Full Text]
|
|